NCT00868985已完成1 期
Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation
Norgine1 个研究点 分布在 1 个国家目标入组 114 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 114
- 试验地点
- 1
- 主要终点
- Electrolyte profile in blood, urine and faeces, serum osmolality and effect on the renin/aldosterone ratio
研究概览
简要总结
The study is to evaluate the influence of three different doses of PEG 3350 with or without electrolytes on the electrolyte balance in patient volunteers with confirmed chronic constipation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subjects written informed consent must be obtained prior to inclusion.
- •Male and female patients between 18 and 70 years of age with confirmed chronic constipation after the run-in period; this is defined as patients who have recorded in their diaries less than 3 bowel motions/week plus one of the following symptoms:
- •Straining during at least 25% of defecations Lumpy or hard stools with at least 25% of defecations Sense of incomplete evacuation with at least 25% of defecation Sensation of ano-rectal blockage with at least 25% of defecation Manula manoeuvres of facilitate at least 25% of defecation
- •Willing and able to follow the entire procedure and to comply with the study instructions.
- •For the subgroup of patient volunteers taking ACE-inhibitors (36 subjects): A history of hypertension, with blood pressure controlled to acceptable levels by a stable regimen of ACE-inhibitors.
排除标准
- •Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months.
- •Subjects who have previously been enrolled in this study.
- •Subjects who are currently or have a history of abuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse eg solvents.
- •Major surgery in within the last 12 months.
- •Malignant tumors within the last 5 years.
- •Uncontrolled blood pressure or terminal cardiac, liver and/or kidney diseases.
- •Clinical relevant acute gastrointestinal tract disease, including evidence of intestinal perforation or obstruction, paralytic ileus, toxic megacolon, severe inflammatory conditions.
- •Acute urinary tract conditions, including cystitis.
- •Patients with diagnosis or evidence of the following diseases: Hypothyroidism, diabetes mellitus, porphyria, pituitary gland insufficiency, pheochromocytoma, glucagonoma, neurological diseases (eg Hirschprung disease, neurofibromatosis, Chagas disease, stroke, autonomous neuropathy, intestinal pseudoobstruction, Multiple sclerosis, medullar injury, Parkinson disease, Shy-Drager syndrome), collagenosis, vasculitis, myopathy (e.g. sclerodermatitis, amyloidosis, dermatomyositis), intoxication with heavy metals (e.g. Pb, As, Hg)
- •Concomitant medication:
- •Use of any oral purgatives/laxatives and prokinetics within the last 14 days prior to dosing.
- •Use of any opioids, anti-cholinergics, tricyclic anti-depressants, MAOIs, Fe preparations, within the 4 weeks prior to dosing.
- •Use of any Ca-antagonists, Beta-blockers or diuretics within the last 4 weeks prior to dosing.
- •other medication which in the opinion of the Investigator could interfere with the principal function of the GI tract.
- •Subject unable to provide written consent.
- •Failure to satisfy the Investigator of fitness to participate for any other reason, including suspected non-compliance.
- •Women of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration, unless they are surgically sterilised/hysterectomised or any other criteria considered sufficiently reliable by the Investigator in individual cases.
- •Patients with electrolytes disturbances or clinical signs of dehydration.
- •Positive test at screening for HIV or hepatitis.
- •Any clinically significant abnormal test results.
研究组 & 干预措施
PEG 3350 plus electrolytes
Experimental
Patients were dosed with PEG 3350 with electrolytes
干预措施: PEG 3350 plus electrolytes (Drug)
PEG 3350 without electrolytes
Experimental
Patients were dosed with PEG 3350 without electrolytes
干预措施: PEG 3350 without electrolytes (Drug)
结局指标
主要结局
Electrolyte profile in blood, urine and faeces, serum osmolality and effect on the renin/aldosterone ratio
时间窗: Ten days
次要结局
- Amount of PEG 3350 in plasma, urine and faeces(Ten days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)ConstipationNCT01885104Bayer65
已完成
3 期
Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic ConstipationConstipationNCT01251822Norgine240
已完成
不适用
Enema versus high doses of PEG 3350 in the treatment of rectal fecal impaction.Childhood constipionNL-OMON23431geen90
已完成
不适用
Enema versus high doses of PEG 3350 in the treatment of rectal faecal impactioConstipationDigestive SystemOther functional intestinal disordersISRCTN71579145Academic Medical Centre (AMC) (Netherlands)90
已完成
1 期
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy SubjectsColorectal CancerNCT01834742Norgine161